GLYXAMBI

empagliflozin and linagliptin · Boehringer Ingelheim Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

19 regulatory and trial events tracked for GLYXAMBI, covering 2015-01-30 to 2026-03-30. Get the full timeline:

Most recent: EMA Authorised: Glyxambi (empagliflozin;linagliptin) — Boehringer Ingelheim International GmbH